Amphetamine News and Research RSS Feed - Amphetamine News and Research

University of Copenhagen researchers move closer to developing antidote against cocaine addiction

University of Copenhagen researchers move closer to developing antidote against cocaine addiction

Researchers at the University of Copenhagen have gained new insight into the mechanism behind a protein dopamine transporter that could help in the development of future medical treatment against cocaine addiction. [More]
LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder." [More]
Health Canada monitors recall of Jetfuel Superburn containing undeclared drug substances

Health Canada monitors recall of Jetfuel Superburn containing undeclared drug substances

"Jetfuel Superburn" is being recalled after Health Canada tests confirmed it contains two undeclared amphetamine-like drug substances that pose serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). [More]
Psychiatric comorbidities predict bipolar disorder in ADHD children

Psychiatric comorbidities predict bipolar disorder in ADHD children

Children with attention deficit/hyperactivity disorder who also have conduct disorder/oppositional defiant disorder or anxiety disorder are at an increased risk of developing bipolar disorder, research shows. [More]
Study finds link between contraband cigarette and illicit drug use among teens in Canada

Study finds link between contraband cigarette and illicit drug use among teens in Canada

A University of Alberta economics professor has discovered a link between contraband cigarette use and illicit drug use among Canadian teens. [More]
HLD-200 successfully meets primary endpoint in Phase III study

HLD-200 successfully meets primary endpoint in Phase III study

Highland Therapeutics Inc., a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. has reported positive top-line results from its recently completed Phase III study. [More]
Mice may hold clues in development of ADHD, autism and bipolar disorder

Mice may hold clues in development of ADHD, autism and bipolar disorder

A darting mouse may hold an important clue in the development of Attention Deficit Hyperactivity Disorder (ADHD), autism and bipolar disorder, according to a study by a Vanderbilt University-led research team recently published in the Proceedings of the National Academy of Sciences. [More]
Study measures effects of high-fat maternal diet on the cognitive functioning of offspring

Study measures effects of high-fat maternal diet on the cognitive functioning of offspring

New research suggests that a high-fat maternal diet during pregnancy and while breastfeeding could have significant and lasting detrimental effects on the brain function and behavior of children. [More]
Illicit drug use, tourism contribute to elevated HIV/AIDS risk in the Dominican Republic

Illicit drug use, tourism contribute to elevated HIV/AIDS risk in the Dominican Republic

The Caribbean has the second highest global human immunodeficiency virus (HIV) prevalence in the world outside of Sub-Saharan Africa, with HIV/AIDS as leading cause of death among people aged 20–59 years within the region. Particularly hard-hit are the Dominican Republic (DR) and Haiti, on the island of Hispaniola, accounting for approximately 70% of all people living with HIV in the Caribbean region. [More]
Highland completes US$25 million offering of Class A Common Shares

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success. [More]
Shire receives FDA guidance on regulatory path for investigational compound SHP 465

Shire receives FDA guidance on regulatory path for investigational compound SHP 465

Shire plc today announced that it has received further guidance from the U.S. Food and Drug Administration on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. [More]
AMRI total revenue increases 15% to $68.2 million in second quarter 2014

AMRI total revenue increases 15% to $68.2 million in second quarter 2014

AMRI today reported financial and operating results for the second quarter ended June 30, 2014. [More]
Study explores how changes in dopamine transporter function linked to brain disorders

Study explores how changes in dopamine transporter function linked to brain disorders

Recent published research in the Journal of Clinical Investigation demonstrates how changes in dopamine signaling and dopamine transporter function are linked to neurological and psychiatric diseases, including early-onset Parkinsonism and attention deficit hyperactivity disorder (ADHD). [More]
Researchers identify genetic mutation that may cause parkinsonism in young people

Researchers identify genetic mutation that may cause parkinsonism in young people

Researchers at the University of Copenhagen and the Copenhagen University Hospital have identified a particular genetic mutation that may cause parkinsonism in young people. The mutation interferes with the brain's transport of the important signal substance dopamine and may also plays a role in mental diseases, e.g. ADHD. [More]
Study shows amphetamines can keep exhaustion at bay in male rats

Study shows amphetamines can keep exhaustion at bay in male rats

Indiana University researchers put male rats to the test to determine the role amphetamines play when used in conjunction with exercise. [More]
Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention deficit hyperactivity disorder). [More]

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Highland Therapeutics Inc., an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD"). [More]

Neurovance closes $6.3M extension to its series A1 financing round to advance development of EB-1020 SR

Neurovance, Inc. today announced that it has closed a $6.3 million extension to its series A1 financing round to further advance development of EB-1020 SR, a non-stimulant, for the treatment of all subtypes of adult ADHD (attention deficit hyperactivity disorder). [More]
Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists at Ume- University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations. [More]

Research highlights value of fathers in both neurobiology and behavior of offspring

Even with today's technology, it still takes both a male and a female to make a baby. But is it important for both parents to raise that child? Many studies have outlined the value of a mother, but few have clearly defined the importance of a father, until now. [More]